Gerda-Marie Rist, Head of Copenhagen Legacy Lab at Wonderful Copenhagen, shared a post on LinkedIn:
“In the future, fewer novel medicines will be approved due to rising costs.
Even though new treatments exist, Danish patients sometimes have to travel to neighbouring countries to receive them – often at their own expense. This means that only those with sufficient financial resources gain access to the best treatment.
In Germany, the process for approving new drugs is different, resulting in faster decision-making and a higher number of approved treatments. Perhaps there is something Denmark could learn from this?
This was the central theme of today’s LEGACY Event at the Bella Center Copenhagen, which we arranged prior to the opening of the European Society of Gynaecological Oncology congress (ESGO). The discussion focused on gynaecological cancers, such as ovarian cancer, but the challenge extends far beyond this area.
Access to new treatment regimens is complex, which is why we brought together both patients, clinicians, decision-makers, and industry representatives for the dialogue.
This was the first time ESGO has worked with legacy initiatives in connection with their congress – but certainly not the last. We hope that today’s event will contribute to improving access to treatment for patients around the world.”
Other articles about ESGO on OncoDaily.
